Adverse effects of drugs on the function of the inner ear

Adverse Drug Reaction Bulletin

Volumn , Issue 186, 1997, Pages 707-710

  Tange, R A ^a,b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b Department of Otology ^*  (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CISPLATIN; LOOP DIURETIC AGENT; QUININE; SALICYLIC ACID DERIVATIVE; STREPTOMYCIN;

HAIR CELL; HEARING LOSS; HUMAN; INNER EAR; NERVE DEGENERATION; OTOTOXICITY; SHORT SURVEY; TINNITUS; VERTIGO;

EID: 0030703109     PISSN: 00446394     EISSN: None     Source Type: Journal    
DOI: 10.1097/00012995-199710000-00001     Document Type: Short Survey

References (30)

1. Morton R. seu Exercittationes de Morbus Universalibus acutis, 1692: 132.
2. Schatz A, Bugie E, Waksman S. Streptomycin, a substance exhibiting antibiotic activity against gram-positive and gram-negative bacteria. Proceedings of the Society for Experimental Biology and Medicine 1944; 55: 66-7.
3. Hinshaw HC, Feldman WH. Streptomycin in the treatment of clinical tuberculosis: a preliminary report. Proceedings of the Mayo Clinic 1945; 20: 313.
4. Causse R, Gondet I, Vallancien B. Action vestibulaire de la streptomycine chez la souris. Clinical Revu. Paris: Society Biologique, 1948; 142: 747.
5. Brummett RE. Drug-induced ototoxicity. Drugs 1980; 19: 412-28.
6. Fee WE jr. Aminoglycoside ototoxicity in the human. Laryngoscope 1980; 90: 1-19.
7. Tange RA. Differences in the cochlear degeneration pattern in the guinea pig as a result of gentamicin and cis-platinum intoxication. Clinical Otolaryngology 1984; 9: 323-7.
8. Tange RA, Huizing EH. Hearing loss and inner ear changes in a patient suffering from severe gentamicin ototoxicity. Archives of Otorhinolaryngology 1980; 228: 113-21.
9. Tange RA. Degenerative ototoxic changes in the cochlea as seen in microdissections and surface preparations. Amsterdam: Thesis Rodopi, 1983.
10. Tange RA, Vuzevski VD. Changes in the stria vascularis of the guinea pig due to cis-platinum. Archives of Otorhinolaryngology 1984; 239: 41-7.
11. Tange RA, Dreschler WA, van der Hulst RJM. The importance of high-tone audiometry in ototoxicity monitoring. Archives of Otorhinolaryngology 1985; 242: 77-81.
12. Kahlmeter G, Dahlager JI. Aminoglycoside toxicity - a review of clinical studies published between 1975 and 1982. Journal of Antimicrobial Chemotherapy 1984; 13(supplement A): 9-22.
13. Fausti SA, Henry JA, Schaffer HI, Olson DJ, Frey RH, McDonald WJ. High-frequency audiometric monitoring for early detection of aminoglycoside ototoxicity. Journal of Infectious Diseases 1992; 165, 1026-32.
14. Prins JM, Büller HR, Kuijper E, Tange RA, Speelman P. Once versus thrice daily gentamicin in patients with serious infections. Lancet 1993; 341: 335-9.
15. Brushwood DB. Government liable for failure to monitor a patient's serum gentamicin concentration in an army hospital. American Journal of Hospital Pharmacy 1992; 49: 1748-50.
16. Usami S, Abe S, Kasai M, et al. Genetic and clinical features of sensorineural hearing loss associated with the 1555 mitochondrial mutation. Laryngoscope 1997; 107: 483-90.
17. Scott PMJ, Griffitths MV. A clinical review of ototoxicity. Clinical Otolaryngology 1994; 19: 3-8.
18. Welling DB, Forrest LA, Goll F. Safety of ototopical antibiotics. Laryngoscope 1995; 105: 472-4.
19. Dixon RL, Cooney DA, Davis RD, Heyman JA, Fleischman RW, Schaeppi U. Preclinical toxicological studies of cis-diammine-dichloroplatinum II. Proceedings of the international congress of chemotherapy. Prague 1971; 2: 243-5.
20. Rossof AH, Slayton RE, Perlia CP. Preliminary clinical experience with cis-diamminedichloroplatinum (II). Cancer 1972; 30: 1451-6.
21. Kopelman J, Budnick AS, Sessions RB, Kramer MB, Wong GY. Ototoxicity of high dose cisplatin by bolus administration in patients with advanced cancers and normal hearing. Laryngoscope 1988; 98: 858-64.
22. Laurell G, Engström B. The combined effect of cisplatin and furosemide on the hearing function in guinea pig. Hearing Research 1989; 38: 19-26.
23. van Zeijl LG, Conijn EA, Rodenburg M, Tange RA. Analysis of hearing loss due to cis-diamminedichloroplatinum-II. Archives of Otorhinolaryngology 1984; 239: 255-62.
24. Vermorken JB, Kapteijn TS, Hart AAM, Pinedo HM. Ototoxicity of cis-diamminedichloroplatinum (II): influence of dose, schedule and mode of administration. European Journal of Cancer and Clinical Oncology 1983; 19: 53-8.
25. Laurell G. Ototoxicity of the anticancer drug cisplatin - clinical and experimental aspects. Scandinavian Audiology Supplementum 1991; 31; 1-48.
26. Maher JF, Schreiner GE. Studies on ethacrynic acid in patients with refractory oedema. Annals of Internal Medicine 1965; 62: 15-29.
27. Gallagher KL, Jones JK. Frusemide-induced Ototoxicity. Annals of Internal Medicine. 1979; 91: 744-5.
28. Bourke E. Frusemide, bumetanide and Ototoxicity. Lancet 1976; 1: 917-18.
29. Harpur ES. Disorders of the ear. In: D'Arcy PF, Griffin JP, eds. Iatrogenic Diseases. Oxford: OUP, 1986: 714-40.
30. Tange RA, Dreschler WA, Claessen FAP, Perenboom RM. Ototoxic reactions of quinine in healthy persons and patients with Plasmodium falciparum infection. Auris Nasus Larynx 1997; 24: 131.